Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

A 20-year-old lost significant hair after one year of treatment, using minoxidil, finasteride, and later dutasteride. They are considering adding RU58841 but are advised to return to finasteride and minoxidil for a year before deciding.

RU58841 is discussed as a potential hair loss treatment, with comparisons to finasteride. There is interest in leaked trial data, but no official clinical validation or approval for RU58841.

A new extended-release oral minoxidil formulation claims to improve hair growth by maintaining steady blood levels, reducing side effects like hypotension, and potentially benefiting female hair loss. However, it is not considered groundbreaking as it builds on existing minoxidil treatments, and its effectiveness compared to current doses is debated.

The conversation discusses GT20029, a drug in Phase II trials that targets androgen receptors with minimal systemic effects, and TDM-105795, a growth stimulant with a different mechanism than minoxidil that may revive papilla stem cells. Both are potential new treatments for hair loss.

Finasteride is discussed as a hair loss treatment with benefits like reduced prostate enlargement and skin aging, but it is not seen as a "fountain of youth." Users report mixed experiences, including side effects like decreased libido and dry eyes.